# LifeMD, Inc.: Form 10-Q for the period ended Sep 30, 2019

- Company: [LifeMD, Inc.](/companies/lfmd.md) (CIK 948320)
- Form: 10-Q
- Filed: 2019-11-14
- Accepted by EDGAR: Nov 14, 2019, 15:45 ET
- Period: 2019-09-30
- Accession: 0001213900-19-023444
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/948320/000121390019023444/f10q0919_conversionlabs.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/948320/000121390019023444/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $680.1k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $2.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $2.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $6.5m | us-gaap:GrossProfit |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | −$973.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | −$2.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-07-01 to 2019-09-30 | $130.9k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2019-01-01 to 2019-09-30 | $431.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | −$943.8k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | −$2.4m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months, 2019-07-01 to 2019-09-30 | 50,674,838 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2019-01-01 to 2019-09-30 | 48,135,466 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | $92.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2019-09-30 | $780.9k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $1.8m | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $2.5m | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $3.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $3.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-09-30 | −$469.8k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 34,884 characters.

#### Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) that reflect management’s current views with respect to future events and financial performance. These statements are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company’s business, industry, and the Company’s operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report. The forward-looking statements made in this report are based only on events or information as of the date on which the statements are made in this report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this report and the documents we refer to in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. These risks include, by way of example and without limitation:

- our ability to successfully commercialize our products and services on a large enough scale to generate profitable operations;
- our ability to maintain and develop relationships with customers and suppliers;
- our ability to successfully integrate acquired businesses or new brands;
- the impact of competitive products and pricing;
- supply constraints or difficulties;
- general economic and business conditions;
- our ability to continue as a going concern;
- our need to raise additional funds in the future;
- our ability to successfully recruit and retain qualified personnel;
- our ability to successfully implement our business plan;
- our ability to successfully acquire, develop or commercialize new products and equipment;
- intellectual property claims brought by third parties; and
- the impact of any industry regulation.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or performance. Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission (“SEC”). We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.

As used in this Quarterly Report on Form 10-Q and unless otherwise indicated, the terms “Company,” “we,” “us,” and “our” refer to Conversion Labs, Inc. (formerly known as Immudyne, Inc.) and our majority-owned subsidiaries LegalSimpli Software, LLC, a Puerto Rico limited liability company (“LegalSimpli”), Conversion Labs PR, LLC (formerly Immudyne PR LLC, now “Conversion Labs PR”), a Puerto Rico limited liability company (“Conversion Labs PR”), Conversion Labs Media, LLC (“CVLB Media”), a Puerto Rico limited liability company, Conversion Labs Rx, LLC (“CVLB Rx”), a Puerto Rico limited liability company, and Conversion Labs Asia Limited, a Hong Kong company (“Conversion Labs Asia”). Unless otherwise specified, all dollar amounts are expressed in United States dollars.

#### Corporate History and Overview

Conversion Labs, Inc. is a diversified online direct-to-consumer marketing and telemedicine company with a portfolio of health and wellness brands. Our products are marketed and sold directly to consumers through advertisements on Facebook, Google, Amazon, and other social media and e-commerce platforms. Secondarily, we also sell our products to traditional retailers, wholesalers and physicians’ offices. After the establishment of a joint venture with GoGoMeds.com, through our majority-owned subsidiary CVLB Rx, in June 2019, we now market branded and generic prescription drugs that are then sold and shipped (via GoGoMeds) online directly to consumers in all 50 states and the District of Columbia. We have also established relationships with independent physicians in 39 states that provide virtual consultations to patients that respond to our online advertisements. We operate our business using a proprietary telehealth technology platform that facilitates a compliant relationship between the patient, provider and pharmacy.

We launched our online direct marketing business in the fourth quarter of 2015 with the establishment of a partnership with Inate Skincare, LLC (“Inate”). Our initial intention was to launch a skin care line containing our proprietary ingredients and to market such products directly to consumers. We entered into a limited liability company operating agreement with our joint venture partners with respect to Inate under the legal name Immudyne PR LLC (“Immudyne PR”). On April 1, 2016, the original operating agreement of Immudyne PR was amended and restated and we increased our ownership and voting interest in Immudyne PR to 78.2%. Concurrent with the name change of the parent company to Conversion Labs, Inc. completed in 2018, Immudyne PR was renamed to Conversion Labs PR LLC (now known as “Conversion Labs PR”). On April 1, 2016, the original operating agreement of Conversion Labs PR was amended and restated and we increased our ownership and voting interest in Conversion Labs PR to 78.2%. On April 25, 2019, the operating agreement of Conversion Labs PR was amended and restated in its entirety to increase the Company’s ownership and voting interest in Conversion Labs PR to 100%.

Our priority is to pursue opportunities to market our products and increase sales. We expect that a significant component of our selling, general and administration expenses going forward will consist of advertising expenses and service fees to retain skilled professionals to market our products through the internet. These aforementioned costs, along with the additional costs resulting from our operations as a public reporting company, could adversely impact our future results of operations.

We historically have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace. We have historically operated with limited capital and have funded operations in the past through the sales of our products and loans and advances from our executives and directors.

#### Our Products

### Shapiro MD

Launched in 2017, Shapiro MD is a brand with a portfolio of over-the-counter and prescription products for hair loss for both men and women. Shapiro MD’s product portfolio began with a patented hair loss product line consisting of a shampoo, conditioner and leave-in foamer for thicker, fuller hair. Shapiro MD’s product offering has now grown to include a U.S. Food and Drug Administration (“FDA”) approved minoxidil product and an over-the-counter supplement for hair loss. We intend to continue adding clinically studied hair loss products to Shapiro MD’s offerings such as finasteride for men and compounded prescription products for both men and women. We believe that Shapiro MD offers one of the most robust portfolio of clinically studied over the counter products and FDA approved drugs for both male and female hair loss.

### iNR Wellness MD

Launched in 2018, iNR Wellness MD is a nutritional supplement for immune and gut support. The iNR Wellness product line is a daily nutritional supplement that contains yeast, oat, and mushroom beta glucans. Beta glucans, or β-Glucans, are a natural extract considered to be “biological response modifiers” that support the immune system. Our three naturally occurring beta glucans have clinically shown to support the human immune system and are commonly used as an OTC supplement to reduce cholesterol levels, maintain healthy blood glucose levels, and support the immune system. Our spokespersons for our iNR Wellness MD brand include Dr. Joseph DiTrolio, a member of the Board of Directors of the Company, Dr. Jack Gilbert, and Dr. Liz Lipski, who are leading doctors/researchers in fields such as urology, microbiology, and nutrition. General scientific research on beta glucans has been conducted in recent years by renowned medical laboratories, including Baylor College of Medicine, U.S. Armed Forces Radiobiology Institute, Stanford University, Harvard University, and North Carolina State University. As more studies are conducted on beta glucans, we believe the potential benefits to human health will continue to gain recognition. Although the Food and Drug Administration (“FDA”) has historically endorsed the consumption of oat glucan/dietary fiber as an aid to lower cholesterol, most of the testing and analysis or scientific research mentioned herein has not been subject to oversight of the FDA or any comparable regulatory body, and no regulatory body has attested to the efficacy of beta glucans in supporting the immune system or treating disease. Further, the marketing of beta glucans is not subject to FDA approval, and we are prohibited by Federal Trade Commission (“FTC”) and FDA regulations from suggesting in advertisements and product labels that our products mitigate, treat, cure or prevent a specific disease or class of disease.

### RexMD

Launched in 2019, RexMD is a mens health brand initially offering personalized treatment plans from licensed physicians in 39 states for erectile dysfunction. After consultiation with a physician, if appropriate, we dispense and ship prescription medication directly to patients. We are initially focused on generic Viagra and Cialis but intend to expand our product offering to include treatment for hair loss, cold sores, genital herpes, mental health, and other common medical conditions for men.

### PDF Simpli

Launched in 2018, PDF Simpli is a PDF conversion software product, which was acquired through the purchase of 51% of the membership interests of LegalSimpli Software, LLC, a Puerto Rico limited liability company, which operates a marketing-driven software solutions business. PDFSimpli enables users to convert, edit and sign PDF documents. As of October 31, 2019, PDFSimpli was ranked in the top 12,000 websites globally, in which it was also ranked in the top 1,200 for specific countries with more than 2.4M registered users globally. Since its launch, PDFSimpli has converted or edited over 3 terabytes of documents for customers from the legal, financial, real-estate and academic sectors. PDFSimpli has over 21,000 active subscriptions as of October 31, 2019.

#### Divestiture of Nutraceutical and Cosmetic Additives Business

Prior to 2018, we manufactured, distributed and sold natural immune support products containing our proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. Beta glucans, or β-Glucans, are a natural extract that are considered to be “biological response modifiers” that support the immune system. The most common sources of beta glucans are from the cell walls of baker’s yeast, the cellulose in plants, the bran of cereal grains and certain fungi and bacteria. In the first quarter of 2018 we sold all assets and liabilities related to our legacy business that manufactured raw yeast beta glucan. As a result of this divestiture, we now solely operate our online direct marketing business through our majority-owned operating subsidiary, Conversion Labs PR.

#### Growth Strategy

We actively seek to acquire, license and develop products and brands with large untapped e-commerce potential and proven business models. We intend to continue to grow revenue and profitability of our four commercial stage consumer and telehealth brands. We also expect that PDFSimpli will continue to grow and will achieve profitability in 2019. We continue to actively seek new brands to buy or license to expand our product offerings and add to our growth.

We have begun selling all of our products in international markets and we believe this represents a significant growth opportunity for us. We also entered into a strategic partnership in Asia in 2018. We are in the process of building an e-commerce infrastructure in Asia and are continuing to explore how to expand our market share in that region.

In early 2019, we also launched a service-based business under the name Conversion Labs Media LLC, which was to be used to run e-commerce marketing campaigns for other online businesses. However, this business was discontinued in 2019 in order to focus on our core business as well the expansion of our telehealth opportunities.

#### Results of Operations

### Comparison of the Three Months Ended September 30, 2019 to the Three Months Ended September 30, 2018

#### Revenue and Operating Expenses

Our revenue, operating expenses and net loss for the three months ended September 30, 2019 and 2018 are summarized as follows:

|  | Three Months Ended September 30, 2019 $% of Sales |  | Three Months Ended September 30, 2018 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Net sales | 3,126,727 |  | 2,037,636 |  |
| Cost of sales | 680,081 | 22% | 534,727 | 26% |
| Gross profit | 2,446,646 | 78% | 1,502,909 | 74% |
| Operating expenses | 3,420,352 | 109% | 2,441,358 | 120% |
| Operating (loss) | (973,706) | (0) | (938,449) | (0) |
| Other income (expenses) | (130,936) | -4% | (147,664) | -7% |
| Net income (loss) | (1,104,642) | -35% | (1,086,113) | -53% |
| Net (loss) income attributable to noncontrolling interests | (160,838) | -5% | (37,318) | -2% |
| Net (loss) income attributable to Conversion Labs, Inc. | (943,804) | -30% | (1,048,795) | -51% |

#### Net Sales

Sales were approximately $3.1 million for the three months ended September 30, 2019, compared to approximately $2.0 million for the three months ended September 30, 2018. This is an increase of approximately $1.0 million or 53% which can primarily be attributed to the Company’s purchase of LegalSimpli’s accretive revenue stream and to an increase in the Company’s revenue for haircare and skincare products.

#### Cost of Sales

Total cost of sales was approximately $680,000 for the three months ended September 30, 2019, compared to approximately $534,000 for the three months ended September 30, 2018. Cost of sales consists primarily of material costs and related overhead directly attributable to the production of our products. Cost of Sales as a percentage of income is 22% for the three months ended September 30, 2019, as compared to 26% for the three months ended September 30, 2018. The increase of approximately $145,000, or 27%, is a result of the increase in sales of 53% and due to the Company’s 2018 purchase of LegalSimpli which has a higher margin than the Company’s legacy sales channels.

#### Gross Profit

Gross profit was approximately $2.5 million for the three months ended September 30, 2019, compared to approximately $1.5 million for the three months ended September 30, 2019, an increase of approximately $940,000 or 63%. The increase in our gross profit was primarily the result of the increased sales of our in-licensed Shapiro MD hair loss product line and due to the increased margin of the Company’s LegalSimpli software revenue stream.

#### Operating Expenses

Total operating expenses increased approximately 40% to approximately $3.4 million for the three months ended September 30, 2019, from approximately $2.4 million for the three months ended September 30, 2018. The increase in our operating expenses between the periods was mostly attributable to our increased social media marketing efforts for our in-licensed patented hair loss shampoo, conditioner and leave-in foam. This increase in marketing expenses was $660,000 or 47% when comparing the three months ended September 30, 2019 to the three months ended September 30, 2018. We also had increased compensation and related expense costs or 42% and increased general and administrative expense of 42% when comparing the three months ended September 30, 2019 to the three months ended September 30, 2018.

#### Net Loss

Net loss for the three months ended September 30, 2019 was approximately $1.1 million, compared to net loss of approximately $1.1 million for the three months ended September 30, 2018. Our net loss for the three months ended September 30, 2019 can be most attributed to our increased marketing efforts.

### Comparison of the Nine Months Ended September 30, 2019 to the Nine Months Ended September 30, 2018

#### Revenue and Operating Expenses

Our revenue, operating expenses and net loss for the Nine months ended September 30, 2019 and 2018 are summarized as follows:

|  | Nine Months Ended September 30, 2019 $% of Sales |  | Nine Months Ended September 30, 2018 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Net sales | 8,524,124 |  | 6,139,551 |  |
| Cost of sales | 2,013,265 | 24% | 1,329,881 | 22% |
| Gross profit | 6,510,859 | 76% | 4,809,670 | 78% |
| Operating expenses | 8,881,099 | 104% | 6,072,112 | 99% |
| Operating (loss) | (2,370,240) | (0) | (1,262,442) | (0) |
| Other income (expenses) | (430,956) | -5% | (205,192) | -3% |
| Income from continuing operations | (2,801,196) | -33% | (1,467,634) | -24% |
| Income from discontinued operations, including gain on sale, net of income taxes | — | 0% | 925,738 | 15% |
| Net income (loss) | (2,801,196) | (0) | (541,896) | (0) |
| Net (loss) income attributable to noncontrolling interests | (375,540) | -4% | (66,160) | -1% |
| Net (loss) income attributable to Conversion Labs, Inc. | (2,425,656) | -28% | (475,736) | -8% |

#### Net Sales

Sales were approximately $8.5 million for the nine months ended September 30, 2019, compared to approximately $6.2 million for the three months ended September 30, 2018. This is an increase of approximately $2.4 million or 39% which can primarily be attributed to the Company’s purchase of LegalSimpli’s accretive revenue stream and to a $1.7 million increase in the Company’s revenue for haircare and skincare products.

#### Cost of Sales

Total cost of sales was approximately $2.0 million for the nine months ended September 30, 2019, compared to approximately $1.3 million for the nine months ended September 30, 2018. Cost of sales consists primarily of material costs and related overhead directly attributable to the production of our products. Cost of Sales increased by $683,000 or 51% which is a result of the increased sales.

#### Gross Profit

Gross profit was approximately $6.5 million for the nine months ended September 30, 2019, compared to approximately $4.8 million for the nine months ended September 30, 2018, an increase of approximately 35%. The increase in our gross profit was primarily the result of the increased sales of our in-licensed patented hair loss shampoo, conditioner and leave-in foam.

#### Operating Expenses

Total operating expenses increased approximately 46% to approximately $8.8 million for the nine months ended September 30, 2019, from approximately $6.1 million for the nine months ended September 30, 2018. The increase in our operating expenses between the periods was mostly attributable to our increased social media marketing efforts for our in-licensed patented hair loss shampoo, conditioner and leave-in foam, which increased approximately $1.7 million over from the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018. The total increase in marketing expenses was $2.0 million or 56% when comparing the nine months ended September 30, 2019 to the nine months ended September 30, 2018. We also had increased compensation and related expense costs or 69% and increased general and administrative expense of 50% when comparing the nine months ended September 30, 2019 to the nine months ended September 30, 2018.

#### Net Loss

Net loss for the nine months ended September 30, 2019 was approximately $2.8 million, compared to net loss of approximately $541,000 for the nine months ended September 30, 2018. Our net loss for the nine months ended September 30, 2019 was mostly attributable to our increased marketing efforts, whereas our low net loss for the nine months ended September 30, 2018 was mostly attributable to the sale of the Company’s legacy business.

#### Liquidity and Capital Resources

### Working Capital

The following table sets forth a summary of working capital as of September 30, 2018 and December 31, 2018:

|  | September 30, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Current assets | $1,761,434 | $1,605,070 |
| Current liabilities | 2,984,176 | 1,192,397 |
| Working capital | $(1,222,742) | $412,673 |

We had a negative net working deficit of $1,222,742 at September 30, 2019, resulting in a decrease of $1,635,415 in working capital from net working capital of $412,673 at December 31, 2018. The ratio of current assets to current liabilities was 0.59 to 1 at September 30, 2019.

### Cash Flows

The following table sets forth a summary of changes in cash flows for the Nine months ended September 30, 2019 and 2018:

|  | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Net cash provided by (used in) operating activities | $92,496 | $(489,201) |
| Net cash (used in) provided by investing activities | (500,000) | 241,445 |
| Net cash used in financing activities | 1,008,303 | 513,649 |
| Change in cash | $600,799 | $265,893 |

28

#### Operating Activities

Net cash provided by operating activities was approximately $92,496 for the nine months ended September 30, 2019 primarily due to increases in accounts payable and accrued expenses of $1.2 million, stock compensation expense of approximately $540,000, amortization of debt discount of approximately $324,000, amortization of intangibles of approximately $251,000 and decreases in inventory of approximately $275,000.

Net cash used in operating activities was approximately $489,201 for the nine months ended September 30, 2018. Cash from operating activities during the nine months ended September 30, 2019 was primarily due to the net loss of approximately $541,000, gain on sale of legacy business of approximately $918,000 which was offset by stock compensation expense of approximately $458,000.

#### Investing Activities

For the nine months ended September 30, 2019, net cash used in investing activities was $500,000 for payments related to the contingent consideration for the purchase of LegalSimpli.

For the Nine months ended September 30, 2018, net cash provided by investing activities was approximately $241,000 for proceeds related to the sale of the legacy business offset by the cash outlaw related to the purchase of LegalSimpli.

#### Financing Activities

For the nine months ended September 30, 2019, net cash provided by financing activities was approximately $1.0 million of which consisted of $1.1 million was received from the issuance of convertible notes, offset by payments to a convertible note holder of $345,000.

For the nine months ended September 30, 2018, net cash provided by financing activities was approximately $513,000 which related to the cash received for convertible notes payable.

#### Going Concern and Future Financing

Our principal demands for liquidity are to increase sales via online marketing, purchase inventory and for sales distribution and general corporate purposes. We incurred negative operating cash flows of our continued operations to date in 2019 as well as in the 2018 fiscal year. As a result, we have substantial doubt about our ability to continue as a going concern.

We will require additional funds to implement our growth strategy for our business. In addition, while we have received capital from various private placements and convertible loans that have enabled us to fund our operations, these funds have been largely used to supplement our working capital, although additional funds are needed for other corporate operational and working capital purposes. At this time and at our current burn rate, we have sufficient capital to fund our operations through the balance of this fiscal year. At this time, we have not determined the amount that may be needed. These funds may be raised through equity financing, debt financing, or other sources, which may result in further dilution in the equity ownership of our shares. There can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis should it be required, or generate significant material revenues from operations, we will not be able to meet our other obligations as they become due and we will be forced to scale down or perhaps even cease our operations.

### Equity Financings

On February 27, 2019, the Company entered into short-term note agreement for $100,000 that was repaid prior to the end of this quarter. As part of the note agreement, the Company issued 100,000 restricted shares of common stock to the note holder valued at $16,000.

### Debt Financings

On August 15, 2019, the Company entered into securities purchase agreements with three accredited investors (the “Investors”). Pursuant to the terms of the Purchase Agreements, the Company issued and sold to the Investors convertible promissory notes (the “Notes”) for the aggregate original principal amount of $1,291,500 and issued warrants (the “Warrants”) to purchase up to 4,679,348 shares of the Company’s common stock. The Warrants are immediately exercisable and have a term of ten years. The Warrants are exercisable at a price per share of $0.28, subject to adjustment as described herein and contain a cashless exercise mechanism.

The Notes mature on the first anniversary of the Closing Date (the “Maturity Date”) and accrue interest at a rate of twelve percent (12%) per annum, subject to adjustments.

The Notes may be converted into shares of the Company’s common stock, at the discretion of the holder, at any time following issuance, unless the conversion or share issuance under the conversion would cause the holder to beneficially own shares in excess of 4.99% of the Company’s common stock. The conversion price for the principal and interest, if any, in connection with voluntary conversion by the Investors shall be $0.23 per share of common stock, subject to adjustment (the “Conversion Price”). In the event the average VWAP (as defined in the Note) for the consecutive ten (10) Trading Days (as defined in the Note) preceding but not including either or both of the ninety (90) day and one hundred and eighty (180) day anniversary of the Closing Date is less than the then Conversion Price in effect either or both on such ninety (90) day and one hundred and eighty (180) day anniversary date, then the Conversion Price with respect to unconverted principal and interest on the Note shall be reduced (and only reduced) to eighty percent (80%) of the VWAP for the ten (10) Trading Days following (but not including) such ninety (90) day and one hundred and eighty (180) day anniversary date, subject to further reduction.

The Notes contain standard event of default provisions, certain covenants and restrictions, including, among others, that, for so long as the Notes are outstanding, the Company will not incur any indebtedness, permit liens on its properties (other than permitted indebtedness or permitted liens under the Notes), make dividends or transfer certain assets.

#### Liquidity and Capital Resources Outlook

The Company has funded operations in the past through the sales of its products, issuance of common stock, and debt securities and through loans and advances from officers and directors. The Company’s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock and/or debt securities.

The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. At September 30, 2019, the Company has an accumulated deficit approximating $15.9 million and a working capital deficit of approximately $1,222,000. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Based on the Company’s cash balance at September 30, 2019, and projected cash needs for the remainder of 2019, management estimates that it will need to increase sales revenue and/or raise additional capital to cover operating and capital requirements for the 2019 year and beyond. Management will need to raise the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company.

#### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

#### Effects of Inflation

We do not believe that inflation has had a material impact on our business, revenues or operating results during the periods presented.

#### Critical Accounting Policies and Estimates

Our significant accounting policies are more fully described in the notes to our financial statements included herein for the quarter ended September 30, 2019 and in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on April 1, 2019.

#### Recently Issued Accounting Pronouncements

Any recently issued accounting pronouncements are more fully described in Note 1 to our financial statements included herein for the quarter ended September 30, 2019.

#### Recently Adopted Accounting Standards

Aside from the below, our recently adopted accounting pronouncements are more fully described in Note 2 to our financial statements included herein for the quarter ended September 30, 2019.

In February 2016, FASB issued ASU No. 2016-02, *Leases* (Topic 842). The standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). This standard will be effective for our interim and annual periods beginning January 1, 2019, and must be applied on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. The Company adopted ASU 2016-02 on January 1, 2019.

## Controls and procedures

As filed, 2,999 characters.

#### Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation and subject to the foregoing, our principal executive officer and principal financial officer concluded that, our disclosure controls and procedures were not effective due to the following material weakness(es) in internal control over financial reporting described below.

- Lack of a functioning audit committee and a lack of a majority of outside directors on the Company’s board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures;
- Inadequate segregation of duties consistent with control objectives;
- Insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines;
- Inadequate security and restricted access to computer systems including a disaster recovery plan;
- Lack of formal written policy for the approval, identification and authorization of related party transactions; and
- No written whistleblower policy.

#### Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended September 30, 2019 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 774 characters.

An investment in our common stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2018 (the “Annual Report”), as filed with the SEC on April 1, 2019, in addition to other information contained in those documents and reports that we have filed with the SEC pursuant to the Securities Act and the Exchange Act since the date of the filing of the Annual Report, including, without limitation, this Quarterly Report on Form 10-Q, in evaluating our company and its business before purchasing shares of our common stock. Our business, operating results and financial condition could be adversely affected due to any of those risks.

Filed Nov 14, 2019.
Source: SEC EDGAR, the filing index for accession 0001213900-19-023444. Last ingested by Listed: Nov 13, 2026, 16:33 ET. No prices; not investment advice.
